Gene Therapy to Target GD2 for Oncology is under clinical development by Bristol-Myers Squibb and currently in Phase I for Osteosarcoma. According to GlobalData, Phase I drugs for Osteosarcoma have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Gene Therapy to Target GD2 for Oncology’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gene Therapy to Target GD2 for Oncology overview
Gene therapy is under development for the treatment of relapsed or refractory neuroblastoma, osteosarcoma and refractory or metastatic GD2-positive sarcoma. It is administered through Intravenous route and constitutes modified natural Killer T cells expressing the third-generation chimeric antigen receptor (CAR) transduced with retroviral vector specific for the disialoganglioside GD2 and the suicide gene inducible caspase 9 (iCasp9).
Bristol-Myers Squibb overview
Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company. It is engaged in the discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, immunology, cardiovascular, and fibrotic diseases. The company offers its products across the world to wholesalers, retail pharmacies, medical professionals, hospitals and government entities. The company has an operational presence in the US, Switzerland, Puerto Rico, Ireland, and the Netherlands. The company conducts research to focus on the discovery and development of novel medicines that address diseases in areas of unmet medical need. BMS is headquartered in Princeton, New Jersey, the US.
For a complete picture of Gene Therapy to Target GD2 for Oncology’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
